The Kang laboratory generated a cell-penetrating synthetic peptide corresponding to the first 1–10 amino acids in Rab22a, based on their discovery that fusion proteins containing Rab22a1–38 bind SmgGDS-607 in osteosarcoma (Liao et al., 2020). The gene discussed is RAB22A; the disease is osteosarcoma.